- Home
- SERV vs TRVI Comparison
SERV vs TRVI Comparison
Compare SERV & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SERV
- TRVI
- Stock Information
- Founded
- SERV 2017
- TRVI 2011
- Country
- SERV United States
- TRVI United States
- Employees
- SERV N/A
- TRVI N/A
- Industry
- SERV Industrial Specialties
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- SERV Consumer Discretionary
- TRVI Health Care
- Exchange
- SERV Nasdaq
- TRVI Nasdaq
- Market Cap
- SERV 682.1M
- TRVI 629.8M
- IPO Year
- SERV N/A
- TRVI 2019
- Fundamental
- Price
- SERV $11.24
- TRVI $5.66
- Analyst Decision
- SERV Strong Buy
- TRVI Strong Buy
- Analyst Count
- SERV 4
- TRVI 8
- Target Price
- SERV $17.00
- TRVI $19.31
- AVG Volume (30 Days)
- SERV 5.7M
- TRVI 2.5M
- Earning Date
- SERV 08-12-2025
- TRVI 08-07-2025
- Dividend Yield
- SERV N/A
- TRVI N/A
- EPS Growth
- SERV N/A
- TRVI N/A
- EPS
- SERV N/A
- TRVI N/A
- Revenue
- SERV $1,306,237.00
- TRVI N/A
- Revenue This Year
- SERV $298.51
- TRVI N/A
- Revenue Next Year
- SERV $586.63
- TRVI N/A
- P/E Ratio
- SERV N/A
- TRVI N/A
- Revenue Growth
- SERV 17.26
- TRVI N/A
- 52 Week Low
- SERV $1.82
- TRVI $2.36
- 52 Week High
- SERV $24.35
- TRVI $7.48
- Technical
- Relative Strength Index (RSI)
- SERV N/A
- TRVI 38.66
- Support Level
- SERV N/A
- TRVI $5.53
- Resistance Level
- SERV N/A
- TRVI $5.96
- Average True Range (ATR)
- SERV 0.00
- TRVI 0.33
- MACD
- SERV 0.00
- TRVI -0.08
- Stochastic Oscillator
- SERV 0.00
- TRVI 8.46
About SERV Serve Robotics Inc. Common Stock
Serve Robotics Inc is developing next-generation robots for last-mile delivery services. It design, develop and operate low-emissions robots on AI-powered robotics mobility platform, that serve people in public spaces, starting with food delivery. Its first product is a zero-emission robot that serves people in public areas, Starting with food delivery. It has developed an AI-robotics mobility platform, with last-mile delivery in cities as its first application.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.